A Swedish company founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark.
Galecto Biotech has raised €79M across 1 funding round from 9 investors, most recently a Series C round in Oct 2018. Based in Copenhagen, Denmark; founded 2011; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2018-10-01 | Series C |
| €79M |
| Bristol Myers-Squibb,HBM Healthcare Investments,M Ventures,Maverick Ventures,Novo Seeds,OrbiMed+3 more |
| View deal → |
